Evidence map›Paper›PMID 41514108›Full record

ArticleBulletin of experimental biology and medicine2025

Antitumor Activity of Poloxamer-188 Solution (Myotive) after Oral and Intravenous Administration in Female BALB/c Mice.

D I Rzhevskiy, R A Dalevich, I N Kravchenko, E S Sadovnikova, S G Semushina, G A Slascheva, V A Kazakov, N A Borozdina, V A Palikov, N M Pankratova and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

D I RzhevskiyBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
R A DalevichBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
I N KravchenkoBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
E S SadovnikovaBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
S G SemushinaBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
G A SlaschevaBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
V A KazakovBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
N A BorozdinaBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia. borozdina@bibch.ru.
V A PalikovBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
N M PankratovaInstitute of Mathematical Problems of Biology, Russian Academy of Sciences - Branch of Keldysh Institute of Applied Mathematics, Russian Academy of Sciences, Pushchino, Russia.
A N PankratovPushchino Branch of Russian Biotechnological University (BIOTECH University), Pushchino, Russia.
I A DyachenkoBranch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia.
E V ArshintsevaMedical Emulsions LLC, Serpukhov, Russia.
S Yu PushkinMedical Emulsions LLC, Serpukhov, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the effectiveness of poloxamer-188 solution (Myotive) administered orally and intravenously at a dose of 48 mg/kg to female BALB/c mice before and after inoculation of colon carcinoma. After oral and intravenous administration of the poloxamer, active tumor necrosis and body weight loss for this reason were observed; a decrease in the tumor volume and normalization of the differential blood cell count and hematological parameters were also seen. Thus, poloxamer-188 is a promising antitumor agent presumably affecting the modified lipid bilayer of tumor cells.

Indexed as

Antineoplastic AgentsColonic NeoplasmsPoloxamerAdministration, IntravenousAdministration, OralAnimalsFemaleMiceMice, Inbred BALB CAntineoplastic AgentsPoloxamerBALB/c micecolon canceremuxol-268poloxamer-188

Identifiers

PMID41514108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.